Cerus Corp CERS:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:11 PM EST
6.44quote price arrow down-0.02 (-0.31%)
Volume
338,357
Close
6.46quote price arrow down-0.06 (-0.92%)
Volume
3,181,187
52 week range
2.71 - 8.87

...

Loading . . .

KEY STATS

  • Open6.49
  • Day High6.62
  • Day Low6.28
  • Prev Close6.52
  • 52 Week High8.87
  • 52 Week High Date12/23/20
  • 52 Week Low2.71
  • 52 Week Low Date03/18/20
  • Market Cap1.087B
  • Shares Out168.22M
  • 10 Day Average Volume2.42M
  • Dividend-
  • Dividend Yield-
  • Beta1.26
  • 1 Year % Change26.54

RATIOS/PROFITABILITY

  • EPS (TTM)-0.37
  • P/E (TTM)-17.66
  • Fwd P/E (NTM)-18.15
  • EBITDA (MRQ)-55.224M
  • ROE (MRQ)-74.42%
  • Revenue (MRQ)114.25M
  • Gross Margin (MRQ)63.98%
  • Net Margin (MRQ)-52.39%
  • Debt To Equity (MRQ)46.34%

EVENTS

  • Earnings Date05/07/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Cerus Corp News

QUOTE FINDER

Profile

MORE
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and...
Daniel Swisher Jr.
Chairman
William Greenman
Chief Executive Officer
Vivek Jayaraman
Chief Operating Officer
Kevin Green CPA
Chief Financial Officer
Address
1220 Concord Ave Ste 600
Concord, CA
94520-4906
United States